ArticleGenome medicine2021
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription.
Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 60 citations in OpenAlex.
- Identification of a novel fiber shaft structural motif and overexpression of key transcripts elucidated in human adenovirus D 10.PLoS pathogens · 2026Article
- Non-Clinical Safety of GRAd Vector-Based COVID-19 and HIV Vaccines Supports a Platform Regulatory Approach.Vaccines · 2026Article
- VITT Pathophysiology: An Update.Vaccines · 2025Review
- Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines.NPJ vaccines · 2024Article
- Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein.NPJ vaccines · 2024Article
- Modeling the health impact of increasing vaccine coverage and nonpharmaceutical interventions against coronavirus disease 2019 in Ghana.Pathogens and global health · 2024Article
- Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)-Insights from Clinical Cases, In Vitro Studies and Murine Models.Journal of clinical medicine · 2023Review
- Article
- COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.Immunity, inflammation and disease · 2023Review
- Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model.Journal, genetic engineering & biotechnology · 2023Article
- Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?Frontiers in medicine · 2023Review
- Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination.iScience · 2022Article
- Article
- Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines.Journal of microbiology (Seoul, Korea) · 2022Review
- E4orf1 SuppressesVaccines · 2022Article
- Vaccine-induced COVID-19 mimicry syndrome.eLife · 2022Article
- Article
- SARS-CoV-2 Spike Protein ExpressionFrontiers in immunology · 2022Article
- Article
- Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects.Oncotarget · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-2 S glycoprotein gene.
methodsWe used direct RNA sequencing to analyse transcript expression from the ChAdOx1 nCoV-19 genome in human MRC-5 and A549 cell lines that are non-permissive for vector replication alongside the replication permissive cell line, HEK293. In addition, we used quantitative proteomics to study over time the proteome and phosphoproteome of A549 and MRC5 cells infected with the ChAdOx1 nCoV-19 vaccine.
resultsThe expected SARS-CoV-2 S coding transcript dominated in all cell lines. We also detected rare S transcripts with aberrant splice patterns or polyadenylation site usage. Adenovirus vector transcripts were almost absent in MRC-5 cells, but in A549 cells, there was a broader repertoire of adenoviral gene expression at very low levels. Proteomically, in addition to S glycoprotein, we detected multiple adenovirus proteins in A549 cells compared to just one in MRC5 cells.
conclusionsOverall, the ChAdOx1 nCoV-19 vaccine's transcriptomic and proteomic repertoire in cell culture is as expected. The combined transcriptomic and proteomics approaches provide a detailed insight into the behaviour of this important class of vaccine using state-of-the-art techniques and illustrate the potential of this technique to inform future viral vaccine vector design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.